Table 4.
Biomarkers and published signatures in advanced disease. The metagene, ABAT and STC2 were compared with the published signatures for Recurrence Score and Genomic Grade Index (GGI) for their relationship with PFS in advanced disease after treatment with tamoxifen (series IV and VI) or aromatase inhibitors (series V).
| Univariate | Bivariate (biomarker together with published signature evaluated) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Metagene score | ABAT | STC2 | |||||||
| Signature | N | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| Series IV. Tam (N = 96) | |||||||||
| Recurrence Score | |||||||||
| low | 35 | 1.00 | 1.11 (0.99–1.24) | 0.085 | 0.84 (0.71–0.99) | 0.036 | 0.94 (0.82–1.09) | 0.430 | |
| moderate | 12 | 1.01 (0.49–2.08) | 0.977 | ||||||
| high | 49 | 1.61 (1.00–2.60) | 0.050 | ||||||
| GGI | 96 | 0.99 (0.90–1.10) | 0.899 | 1.14 (1.03–1.26) | 0.010 | 0.80 (0.69–0.93) | 0.005 | 0.90 (0.78–1.03) | 0.113 |
| TAM78 | 62 | 2.34 (1.34–4.11) | 0.003 | 1.11 (0.98–1.27) | 0.102 | 0.86 (0.71–1.04) | 0.130 | 0.94 (0.79–1.11) | 0.455 |
| ROR‐S | |||||||||
| low | 33 | 1.00 | 1.10 (0.97–1.24) | 0.141 | 0.85 (0.72–1.01) | 0.065 | 0.96 (0.83–1.10) | 0.534 | |
| moderate | 30 | 1.42 (0.82–2.46) | 0.216 | ||||||
| high | 33 | 1.93 (1.14–3.25) | 0.014 | ||||||
| ROR‐P | |||||||||
| low | 23 | 1.00 | 1.13 (1.01–1.26) | 0.039 | 0.80 (0.67–0.96) | 0.018 | 0.91 (0.78–1.06) | 0.230 | |
| moderate | 37 | 0.93 (0.53–1.65) | 0.816 | ||||||
| high | 36 | 1.34 (0.77–2.33) | 0.307 | ||||||
| Series V. AI (N = 84) | |||||||||
| Recurrence Score | |||||||||
| low | 18 | 1.00 | 1.23 (1.08–1.42) | 0.003 | 0.77 (0.62–0.95) | 0.013 | 0.79 (0.67–0.93) | 0.004 | |
| moderate | 7 | 1.85 (0.64–5.36) | 0.259 | ||||||
| high | 59 | 2.86 (1.34–6.07) | 0.006 | ||||||
| GGI | 84 | 3.64 (1.87–7.08) | <0.001 | 1.19 (1.03–1.38) | 0.019 | 0.84 (0.67–1.05) | 0.124 | 0.84 (0.71–0.99) | 0.043 |
| TAM78 | 84 | 1.80 (1.08–3.00) | 0.023 | 1.26 (1.11–1.44) | 0.001 | 0.74 (0.60–0.93) | 0.008 | 0.76 (0.65–0.88) | <0.001 |
| ROR‐S | |||||||||
| Low | 24 | 1.00 | 1.19 (1.03–1.37) | 0.016 | 0.82 (0.66–1.03) | 0.087 | 0.83 (0.71–0.97) | 0.018 | |
| moderate | 31 | 1.20 (0.61–2.36) | 0.603 | ||||||
| high | 29 | 3.20 (1.65–6.21) | 0.001 | ||||||
| ROR‐P | |||||||||
| low | 18 | 1.00 | 1.19 (1.03–1.38) | 0.017 | 0.80 (0.64–1.00) | 0.050 | 0.82 (0.71–0.96) | 0.015 | |
| moderate | 38 | 1.79 (0.84–3.82) | 0.132 | ||||||
| high | 28 | 3.94 (1.81–8.59) | 0.001 | ||||||
| Series VI. Tam (N = 231), qRT‐PCR | |||||||||
| Recurrence Score | |||||||||
| low | 65 | 1.00 | 1.05 (0.99–1.11) | 0.134 | 0.88 (0.80–0.97) | 0.011 | 0.96 (0.90–1.02) | 0.196 | |
| moderate | 13 | 1.90 (1.00–3.60) | 0.048 | ||||||
| high | 131 | 2.39 (1.70–3.37) | <0.001 | ||||||
| GGI | 226 | 1.53 (1.29–1.81) | <0.001 | 1.06 (1.01–1.12) | 0.032 | 0.89 (0.81–0.97) | 0.009 | 0.94 (0.89–1.01) | 0.057 |